Skip to main content
Fig. 6 | Critical Care

Fig. 6

From: The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients

Fig. 6

Thirty-day survival of N-AKI, AKI, and AKI-RRT patients. The Kaplan-Meier analysis including the first 30 days of ICU stay indicated a significant survival benefit for patients without AKI (p < 0.0001). The AKI-RRT group had the lowest survival rate and AKI patients who did not receive RRT had intermediate survival rates. AKI patients with acute kidney injury, AKI-RRT patients with acute kidney injury treated with renal replacement therapy, N-AKI patients without AKI

Back to article page

Critical Care

ISSN: 1364-8535